Search Results

Bioverativ Inc. today reported financial results for the third quarter of 2017.

Bioverativ announced today that its 2018 Annual Meeting of Stockholders has been scheduled for April 25, 2018.

More than 15,000 people with hemophilia in 40 developing countries have already been treated following Bioverativ and Sobi’s unprecedented donation of factor therapy to the WFH Humanitarian Aid Program

As of December 31, 2017, Bioverativ had $436.5 million in cash and cash equivalents and no debt.

It took more than 8 months and a series of sweetened offers, but Sanofi was able to close their $11.6B deal to buy Bioverativ without triggering an auction.

On Wednesday, February 14, 2018, at 8:00 a.m. EST, the company will host a live webcast with Bioverativ management.

A little more than one year after Flagship Pioneering launched Sigilon Therapeutics, the company has a new chief executive officer. This morning Sigilon announced Bioverativ veteran Rogerio Vivaldi will helm the Cambridge, Mass.-based company.

Bioverativ presented data demonstrating that BIVV009, its first-in-class monoclonal antibody currently in Phase 3 clinical development for the treatment of cold agglutinin disease (CAgD), was generally well tolerated, rapidly halted hemolysis, and improved anemia in six of six severely anemic primary CAgD patients in a Phase 1b clinical trial.

Bioverativ today announced the publication of a retrospective analysis investigating the use of ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] for immune tolerance induction (ITI).